Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Tag Archives: Warren Woessner
Top Patent Law Stories In 2015
I will try to keep this post as brief as possible, since I posted at length on all of the stories. There was a lot of IP action in 2015 – much involving the Fed. Cir. and Supreme Court’s resolution … Continue reading
Patenting “Natural Products” Down-Under Post-Myriad
Although the Australian High Court held that claims to naturally occurring DNA (e.g., BRCA1 nucleic acid) were not patent eligible because they were not a “manner of manufacture,” since the encoded information therein was not “made” by human action, in … Continue reading
Posted in Non-U.S. Practice
Tagged Australia, biotechnology, biotechnology law, biotechnology news, intellectual property, ip, Myriad, Patent Law, Warren Woessner
1 Comment
Why Did the Chicken Cross the Road? To Get New Genes!
Jay Cormier has a new post on the FDA Law Blog called “Tastes Like Chicken: Second ‘BioPharm’ Animal Approved to Produce Biological to Treat Orphan Disease Includes 6th Rare Pediatric Disease Priority Review Voucher.” He writes: On December 8, 2015, … Continue reading
Posted in Supreme Court News
Tagged BioPharm, FDA, intellectual property, ip, Jay Cormier, Patent Law, patents, Warren Woessner
Leave a comment
Ariosa v. Sequenom – Rehearing En Banc Denied
Not surprisingly, the Fed. Cir., on December 2nd, denied Sequenom’s petition for rehearing en banc of the invalidation of certain of the claims of U.S. Pat. No. 6,258,540 which were directed to methods of detecting and using cffDNA. (Appeal no. … Continue reading